Current stock page

Financial Data

BCRX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

BCRXBioCryst Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$7.61−$0.07 (−0.91%)

Latest quote

  • Momentum
    42
  • Value
    86
  • Quality
    64
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$180.29M$218.25M$156.41M$406.56M$159.4M$163.35M$145.53M$131.53M
Gross Profit$178.72M$214.41M-$546.73M$396.64M$156.87M$160.56M$140.97M$125.4M
Operating Income$53.33M$98.47M-$701.6M$260.39M$29.59M$29.79M$21.23M-$4.51M
Net Income$37.92M$78.4M-$721.81M$245.85M$12.9M$5.09M$32K-$26.8M
EPS$0.15$0.31-$2.98$1.17$0.06$0.02$0-$0.13
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$32.98M$104.34M-$62.14M$276.04M$41.62M$41.3M-$27.52M-$5.21M
Capital Expenditure-$233K-$209K-$403K-$802K-$1.34M-$179K-$143K-$675K
Free Cash Flow$32.75M$104.13M-$62.54M$275.23M$40.28M$41.12M-$27.66M-$5.89M
Net Cash Provided By Operating Activities$32.98M$104.34M-$62.14M$276.04M$41.62M$41.3M-$27.52M-$5.21M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$591.07M$557.85M$465.05M$514.16M$446.42M$457.19M$480.05M$490.42M
Total Debt$828.2M$409.86M$858.08M$438.87M$683.11M$703.18M$829.29M$841.42M
Cash And Cash Equivalents$96.97M$154.97M$172.45M$89.74M$84.08M$88.03M$105.48M$104.92M
Total Liabilities$988.45M$1.01B$1.02B$633.31M$834.31M$878.78M$931.97M$966.35M
Total Stockholders Equity-$397.38M-$454.29M-$553.84M-$119.15M-$387.89M-$421.59M-$451.93M-$475.93M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio———6.56————
P/B ratio————————
P/S ratio2.02———————
Debt To Equity————————
Free Cash Flow Yield17.12%14.85%13.75%18.99%3.22%0.86%-1.22%-3.09%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio———6.56————
P/B ratio————————
P/S ratio2.02———————
Return On Equity————————
Debt To Equity————————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-5.64x
Pb-4.9x
Revenue Growth Yoy13.11%
EPS Growth Yoy144.30%
Gross Margin25.28%
Operating Margin-30.10%
ROE94.36%
ROIC-65.42%
Debt To Equity-2.08
FCF Yield17.85%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$7.61
Volume2.32M
RSI (14)40.74
MACD-0.18
MACD signal-0.15
MACD histogram-0.03
ADX (14)15.17
SMA (50)$8.23
SMA (200)$8.80
ATR (14)$0.35
Historical volatility (annualized)45.23%
Volume (20-day average)5.77M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score55/100
Beta0.65
Annual volatility48.06%
Max Drawdown-32.22%
Sharpe Ratio0.36
VaR (95%, 1-day)-4.13%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BCRX Financial Data FAQ

What is BioCryst Pharmaceuticals, Inc.'s revenue?

BioCryst Pharmaceuticals, Inc.'s revenue is one of the core financial data points for BCRX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is BioCryst Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether BioCryst Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BCRX's EPS?

BCRX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is BioCryst Pharmaceuticals, Inc.'s net income?

BioCryst Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does BioCryst Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash BioCryst Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does BioCryst Pharmaceuticals, Inc. have?

Cash and debt help frame BCRX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.